Research and Markets: Managing Clinical Investigator Compensation - It is Simply Not Enough to Depend on Third Parties to Manage Compensation
* Reuters is not responsible for the content in this press release.
DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/fd9d2d/managing_clinical) has announced the addition of Cutting Edge Information's new report "Managing Clinical Investigator Compensation" to their offering. The most up-to-date clinical investigator compensation benchmarks: Improve cost-effectiveness of investigator compensation - and ensure compliance. Intense scrutiny and regulation besiege pharma's commercial relationships with physicians - and now all signs point to such pressure being directed at the clinical side. The next area headed for regulatory scrutiny is compensation to clinical investigators. Investigations into instances of possible wrongdoing have already occurred, with more likely to follow. In an increasingly inhibitive environment, is your company safeguarded against regulatory checks? Concerned about overpaying physicians? The new culture demands new and transparent tactics. It is simply not enough to depend on third parties to manage compensation. Companies should know for certain how much a physician and facility are receiving. Managing Clinical Investigator Compensation (PH126) provides easy and convenient access to the most up-to-date, detailed investigator compensation benchmarks. Use the data to build accurate and specific pay ranges. Compare your compensation rates to those of other companies and to investigators and improve cost controls. Understand the role of CROs in determining pay structure. Apply proven documentation and calculation strategies that will enable efficient negotiating and guarantee compliance. Keep up with the latest trends on investigator compensation. Learn why companies must be diligent and be proactive in recording payments - they must take action before action is taken upon them. Cutting Edge Information brings significant knowledge and experience in researching the commercial Fair Market Value (FMV) arena. CEI has also conducted extensive research about clinical operations. To develop a comprehensive study, our analysts compiled survey data from investigators and companies across 13 therapeutic areas. More than 50 leading pharma, biotech and medical device companies of all sizes contributed. Use the data benchmarks to: * Control costs * Establish current, market based payments to investigators * Develop regulation-proof calculation and documentation methods * Stay current on the latest FMV regulation concerns and trends Key Topics Covered: * Executive Summary * Study Methodology * Study Definitions * Profiled Companies and Therapeutic Areas * Five Key Findings and Recommendations * Investigator Compensation in a Constricting Regulatory Environment * Investigator Compensation: Industry Data * Investigator Compensation: Investigator Data * Charts and Graphics * Executive Summary Companies Mentioned in this Report: * Autoimmune * Cardiology and Thrombosis * CNS/Psychology * Dermatology * Endocrinology * Gastroenterology * Hematology * Infectious Diseases * Medical Devices * Musculoskeletal * Oncology * Respiratory * Women's Health For more information visit http://www.researchandmarkets.com/research/fd9d2d/managing_clinical Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters